Lipoglycopeptide antibiotic: Class Overview and Comparison
Quick answer: Lipoglycopeptide antibiotic are a class of medicines used for specific therapeutic indications. iMedic covers 5 lipoglycopeptide antibiotic substances. Below is a comparison table linking to detailed pages for each.
Lipoglycopeptide antibiotic on iMedic (5 substances)
| Substance | Primary indications | Mechanism | Common dose |
|---|---|---|---|
| Dalbavancin | Acute bacterial skin and skin structure infections (ABSSSI) | Lipoglycopeptide that binds D-Ala-D-Ala terminus of peptidoglycan precursors, in | 1500 mg IV single dose, or 1000 mg IV followed by 500 mg one week later |
| Dalbavancin Baxter | Acute bacterial skin and skin structure infections (ABSSSI) | Lipoglycopeptide that binds D-Ala-D-Ala terminus of peptidoglycan precursors, in | 1500 mg IV single dose, or 1000 mg IV followed by 500 mg one week later |
| Orbactiv | Acute bacterial skin and skin structure infections (ABSSSI), Gram-positive infections including MRSA | Oritavancin inhibits bacterial cell wall synthesis and disrupts membrane integri | 1200 mg single IV infusion (or 1200 mg loading then 800 mg) |
| Tenkasi | Acute bacterial skin and skin structure infections | Brand name for oritavancin; inhibits bacterial cell wall synthesis and disrupts | 1200 mg single IV infusion |
| Xydalba | Acute bacterial skin and skin structure infections | Inhibits bacterial cell wall synthesis by binding the D-alanyl-D-alanine terminu | 1500 mg IV single dose or 1000 mg followed by 500 mg one week later |
About Lipoglycopeptide antibiotic
Lipoglycopeptide antibiotic share a common mechanism of action and clinical use. Specific dosing, side effects, contraindications, and drug interactions vary between individual substances within the class. Click any substance above for full prescribing information and patient guidance.
Common considerations across the class
- Indication-specific selection: Different members may be preferred for different conditions or patient populations
- Dose equivalence: Members of the same class are not always interchangeable on a 1:1 dose basis
- Drug interactions: Class members often share interaction profiles (e.g., CYP enzyme effects) but individual variation matters
- Side effects: Some side effects are class-wide; others are substance-specific
- Contraindications: Individual contraindications may not generalize across the class
Always consult the prescribing information for the specific medicine prescribed and discuss with your clinician.
Frequently asked questions
What are Lipoglycopeptide antibiotic?
Lipoglycopeptide antibiotic are medicines that share a common mechanism of action used for specific therapeutic indications. iMedic currently covers 5 substances in this class with detailed pages for each.
Are all Lipoglycopeptide antibiotic interchangeable?
No. While medicines in the same class share a mechanism, they differ in potency, dosing, drug interactions, and tolerability. Switching between them is a clinical decision based on individual response, side effects, and treatment goals.
How do I choose between different Lipoglycopeptide antibiotic?
Selection depends on the specific clinical indication, patient factors (age, comorbidities, kidney/liver function, other medications), tolerability of side effects, cost, and clinician preference. This is a prescribing decision.
Are Lipoglycopeptide antibiotic available as generics?
Most well-established class members are available as generic alternatives, often substantially less expensive than brand-name versions while clinically equivalent. Newer members may still be brand-only.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.